ImClone Systems Inc (formerly IMCL)

[Telephonics]

Merck Announces Joint Agreement With ImClone and Bristol-Myers Squibb for
Erbitux in Japan

• Co-development and co-commercialization of Erbitux in metastatic
colorectal
cancer upon health authority approval

Darmstadt, October 17, 2007 – Merck KGaA announced today that it has
established an agreement with ImClone Systems Incorporated and
Bristol-Myers Squibb Company for the co-development and
co-commercialization of Erbitux® (cetuximab) in Japan if approved by the
Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Under terms of
the co-development and co-commercialization agreement, Merck, ImClone
Systems and Bristol-Myers Squibb will jointly market the product under the
common trademark Erbitux in Japan for the treatment of metastatic
colorectal cancer (CRC), as well as for the treatment of any other cancers
that the parties decide to pursue. Merck and BMS will utilize their
respective sales forces in Japan and the three companies will share
development costs, sales and marketing expenses, and profits realized as a
result of the agreement. Merck Serono Japan will distribute the product and
book the sales for the collaboration.



The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/65519DEA4C96104CC1257376004DE2EA/$File/Japan-e.pdf




Merck's news releases are available at this address:
http://media.merck.de
You may change your subscription at any time by following this link:
http://subscribe.merck.de